Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 89 (2) , 204-209
- https://doi.org/10.1016/s0002-9149(01)02201-9
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxenGut, 2001
- IndobufenDrugs & Aging, 2001
- Rofecoxib, a New Cyclooxygenase 2 Inhibitor, Shows Sustained Efficacy, Comparable With Other Nonsteroidal Anti-inflammatory Drugs: A 6-Week and a 1-Year Trial in Patients With OsteoarthritisArchives of Family Medicine, 2000
- COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacinGut, 2000
- The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritisClinical Therapeutics, 1999
- Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2Rheumatology, 1999
- Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trialClinical Therapeutics, 1999
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarctionEuropean Heart Journal, 1993
- A Rapidly Converging Algorithm for Exact Binomial Confidence Intervals About the Relative Risk in Follow-up Studies with Stratified Incidence-Density DataEpidemiology, 1990